We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+19.36%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$74.6B
AUM Growth
+$11.6B
Cap. Flow
+$749M
Cap. Flow %
1%
Top 10 Hldgs %
23.84%
Holding
3,748
New
262
Increased
1,669
Reduced
1,459
Closed
235

Sector Composition

Rank Sector Weight
1 Technology 14.03%
2 Healthcare 8.95%
3 Financials 8.03%
4 Consumer Discretionary 6.23%
5 Industrials 5.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HL icon
3326
Hecla Mining
HL
$11.8B
$58K ﹤0.01%
17,873
+7,782
+77% +$21.5K
UUU icon
3327
Universal Safety Products Inc
UUU
$10.3M
$58K ﹤0.01%
73,513
IMV
3328
DELISTED
IMV Inc. Common Shares
IMV
$58K ﹤0.01%
1,881
-523
-22% -$13.2K
LAC
3329
DELISTED
Lithium Americas Corp. Common Shares
LAC
$58K ﹤0.01%
11,200
CMU
3330
DELISTED
MFS High Yield Municipal Trust
CMU
$57K ﹤0.01%
14,125
-96,631
-87% -$385K
STOR
3331
CALL
DELISTED
STORE Capital Corporation
STOR
$57K ﹤0.01%
+75,600
New +$1.51M
MBII
3332
DELISTED
Marrone Bio Innovations, Inc.
MBII
$57K ﹤0.01%
48,489
-1,812
-4% -$1.68K
CME icon
3333
CALL
CME Group
CME
$94B
$56K ﹤0.01%
74,200
+6,400
+9% +$1.15M
ACER
3334
DELISTED
Acer Therapeutics Inc
ACER
$56K ﹤0.01%
16,200
CPE
3335
DELISTED
Callon Petroleum Company
CPE
$55K ﹤0.01%
4,739
+3,578
+308% +$31.7K
KDNY
3336
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$54K ﹤0.01%
4,690
GSKY
3337
DELISTED
GreenSky, Inc. Class A Common Stock
GSKY
$54K ﹤0.01%
11,107
NG icon
3338
CALL
NovaGold Resources
NG
$3.41B
$52K ﹤0.01%
51,800
+21,300
+70% +$216K
TMUSR
3339
DELISTED
T-Mobile US, Inc. Subscription Rights Expiring 7/27/2020
TMUSR
$52K ﹤0.01%
+307,558
New +$86.4K
CDTX
3340
DELISTED
Cidara Therapeutics
CDTX
$51K ﹤0.01%
+692
New +$44.8K
CVX icon
3341
CALL
Chevron
CVX
$382B
$51K ﹤0.01%
72,100
+5,900
+9% +$528K
MOBL
3342
DELISTED
MobileIron, Inc.
MOBL
$51K ﹤0.01%
10,280
ABBV icon
3343
CALL
AbbVie
ABBV
$441B
$50K ﹤0.01%
33,800
+1,100
+3% +$96.8K
EOD
3344
Allspring Global Dividend Opportunity Fund
EOD
$287M
$50K ﹤0.01%
11,585
ZYNE
3345
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$50K ﹤0.01%
+14,720
New +$69.6K
AMGN icon
3346
CALL
Amgen
AMGN
$227B
$49K ﹤0.01%
14,400
-1,600
-10% -$365K
KGC icon
3347
CALL
Kinross Gold
KGC
$32.8B
$49K ﹤0.01%
+57,000
New +$370K
FMO
3348
DELISTED
Fiduciary/Claymore Energy Infrastructure Fund
FMO
$49K ﹤0.01%
5,342
-19,061
-78% -$178K
ENDP
3349
DELISTED
Endo International plc
ENDP
$48K ﹤0.01%
13,983
PARA
3350
CALL
DELISTED
Paramount Global Class B
PARA
$47K ﹤0.01%
+51,900
New +$1M

Similar funds

Raymond James & Associates's Q2 2020 Portfolio in Review

As of Q2 2020, Raymond James & Associates held 3,748 positions worth $74.6B, up 18% from $63B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q2 2020 filing shows 262 new, 1,669 increased, 1,459 reduced and 235 closed positions. Its largest new stake was Carrier Global: 1,148,017 shares worth $25.5M. The largest sale was iShares Core MSCI EAFE ETF, an estimated $487M.

By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 12% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q2 2020 buy was Carrier Global: 1,148,017 shares worth $25.5M.
  • Raymond James & Associates added most to iShares Broad USD High Yield Corporate Bond ETF in Q2 2020, an estimated $312M increase.
  • Raymond James & Associates's biggest Q2 2020 reduction was iShares Core MSCI EAFE ETF, cutting an estimated $487M.
  • Raymond James & Associates fully exited Raytheon Company in Q2 2020, selling an estimated $73.9M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $74.6B portfolio in Q2 2020.
  • Raymond James & Associates opened 262 new positions and closed 235 in Q2 2020.
  • Raymond James & Associates's portfolio value rose 18% quarter-over-quarter to $74.6B.

Based on Raymond James & Associates's 13F filing for Q2 2020, filed 28 Jul 2020.